King, Purdue Pharma neurology news

King Pharmaceuticals and Purdue settled a suit related to Purdue's U.S. Patent No. 7,658,939, a continuation of U.S. Patent No. 6,696,088, which covers tamper-resistant oral opioid agonist formulations. Under the settlement, Purdue agreed not to sue King over the manufacture, use or sale of Embeda extended-release morphine/naltrexone. King will pay Purdue an upfront payment plus royalties on sales of Embeda for the duration of any valid claims on the '939 and '088 patents. King also agreed not to challenge certain Purdue patents, including the '088 and '939 patents, as they may relate to Embeda. ...